Trial Profile
A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Eftrenonacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Acronyms PREVENT
- Sponsors Swedish Orphan Biovitrum
- 31 Jan 2023 According to a Sobi media release, pooled analysis of real-world effectiveness and safety of a recombinant Factor VIII Fc in patients with haemophilia A by age groups data to be presented at EAHAD 2024.
- 03 May 2022 Status changed from active, no longer recruiting to completed.
- 06 Jul 2021 According to a Swedish Orphan Biovitrum media release, interim analysis from the study will be presented at the virtual ISTH 2021, the 29th Congress of the International Society on Thrombosis and Haemostasis.